

CORRECTION

Open Access



Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]

Jeremie Calais^{1*}, Johannes Czernin^{1*}, Wolfgang P. Fendler^{1,2}, David Elashoff³ and Nicholas G. Nickols^{4,5}

Correction to: BMC Cancer

<https://doi.org/10.1186/s12885-018-5200-1>

Following publication of the original article [1], we have been notified that one of the author names was listed incorrectly. Both incorrect and correct author names are presented below. The original publication has been corrected.

- Originally published name:
Nicholas Nicholas G. Nickols
- Correct name:
Nicholas G. Nickols

Author details

¹Department of Molecular & Medical Pharmacology, Ahmanson Translational Theranostics/ Imaging Division, University of California, Los Angeles, USA.

²Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.

³Department of Medicine Statistics Core (DOMStat), UCLA CTSI Biostatistics and Computational Biology, University of California, Los Angeles, USA.

⁴Department of Radiation Oncology, University of California, Los Angeles, USA.

⁵Department of Radiation Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

Received: 9 January 2019 Accepted: 9 January 2019

Published online: 21 January 2019

Reference

1. Calais, et al. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. *BMC Cancer*. 2018;19:18. <https://doi.org/10.1186/s12885-018-5200-1>.

* Correspondence: jcalais@mednet.ucla.edu; jczernin@mednet.ucla.edu

¹Department of Molecular & Medical Pharmacology, Ahmanson Translational Theranostics/ Imaging Division, University of California, Los Angeles, USA

Full list of author information is available at the end of the article

